Humoral immunity in hand transplantation: Anti-HLA and non-HLA response

Human Immunology

Volumn 75, Issue 8, 2014, Pages 859-862

  Banasik, Mirosław ^a   Jabłecki, Jerzy ^b   Boratyńska, Maria ^a   Kamińska, Dorota ^a   Kościelska Kasprzak, Katarzyna ^a   Bartoszek, Dorota ^a   Chełmoński, Adam ^b   Hałoń, Agnieszka ^a   Baran, Wojciech ^a   Klinger, Marian ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Subdepartament of Replantation of Limbs St Hedwig District Hospital in Trzebnica   (Poland)

Author keywords

Anti HLA antibodies; Antibody mediated rejection; Hand transplantation; Non HLA antibodies

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIBODY; BASILIXIMAB; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN RECEPTOR ANTIBODY; HLA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECEPTOR ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIBODY; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; FEMALE; GRAFT RECIPIENT; HAND TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; ALLOTRANSPLANTATION; BIOSYNTHESIS; DONOR; GENE EXPRESSION; GENETICS; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; GENE EXPRESSION; GRAFT REJECTION; HAND TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; ISOANTIBODIES; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ENDOTHELIN; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84905108126     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.06.010     Document Type: Article

References (34)

1. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 2003, 3:665-673.
2. Cai J., Terasaki P.I. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005, 66:334-342.
3. Banasik M., Boratynska M., Koscielska-Kasprzak K., et al. The impact of de novo donor-specific anti-human leukocyte antigen antibodies on 5-year renal transplant outcome. Transpl Proc 2013, 45:1449-1452.
4. Banasik M., Boratynska M., Nowakowska B., et al. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients. Transpl Proc 2007, 39:2718-2720.
5. Banasik M., Klinger M. Chronic allograft nephropathy-immunologic and nonimmunologic factors. Ann Transplant 2006, 11:7-10.
6. Reinsmoen N.L. Role of angiotensin II type 1 receptor-activating antibodies in solid organ transplantation. Hum Immunol 2013, 74:1474-1477.
7. Dragun D., Hegner B. Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation. Contrib Nephrol 2009, 162:129-139.
8. Banasik M., Boratynska M., Koscielska-Kasprzak K., et al. Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal transplantation. Transpl Proc 2013, 45:1462-1465.
9. Taniguchi M., Rebellato L.M., Cai J., et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant 2013.
10. Giral M., Foucher Y., Dufay A., et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 2013, 13:2567-2576.
11. Kaufman C.L., Ouseph R., Blair B., et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant 2012, 12:1004-1016.
12. Morelon E., Kanitakis J., Petruzzo P. Immunological issues in clinical composite tissue allotransplantation: where do we stand today?. Transplantation 2012, 93:855-859.
13. Hautz T., Zelger B.G., Weissenbacher A., et al. Standardizing skin biopsy sampling to assess rejection in vascularized composite allotransplantation. Clin Transplant 2013, 27:E81-90.
14. Starzl R., Brandacher G., Lee W.P., et al. Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation. Clin Dev Immunol 2013, 2013:402980.
15. Worthington J.E., Martin S., Al-Husseini D.M., et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003, 75:1034-1040.
16. Mizutani K., Terasaki P., Rosen A., et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005, 5:2265-2272.
17. Zakliczynski M., Pyka L., Trybunia D., et al. Influence of panel reactive antibodies (PRA) on perioperative course in patients undergoing elective cardiac surgery procedures, and impact of these procedures on PRA occurrence. Ann Transplant 2006, 11:4-11.
18. Durlik M. Management of highly sensitized patients-deceased donor. Ann Transplant 2006, 11:48-50.
19. Youinou P. New target antigens for anti-endothelial cell antibodies. Immunobiology 2005, 210:789-797.
20. Sun Q., Liu Z., Chen J., et al. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin J Am Soc Nephrol 2008, 3:1479-1486.
21. Glotz D., Lucchiari N., Pegaz-Fiornet B., et al. Endothelial cells as targets of allograft rejection. Transplantation 2006, 82:S19-21.
22. Sun Q., Cheng Z., Cheng D., et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int 2011, 79:655-662.
23. Dragun D., Muller D.N., Brasen J.H., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
24. Dragun D. Agonistic antibody-triggered stimulation of angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant 2007, 22:1819-1822.
25. Hiemann N.E., Meyer R., Wellnhofer E., et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012, 94:919-924.
26. Banasik M., Boratynska M., Koscielska-Kasprzak K., et al. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes. Transpl Immunol 2014, 30:24-29.
27. Banasik M., Boratynska M., Kooecielska-Kasprzak K., et al. The influence of Non-HLA antibodies directed against angiotensin Ii type 1-receptor (At1r) on early renal transplant outcomes. Transpl Int 2013, 26. 38-38.
28. Banasik M., Boratynska M., Koscielska-Kasprzak K., et al. The impact of non-HLA antibodies directed against endothelin-1 type a receptors (etar) on early renal transplant outcomes. Nephrol Dial Transplant 2013, 28. 282-82.
29. Banasik M., Boratynska M., Koscielska-Kasprzak K., et al. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes. Transplant Immunol 2013.
30. Angaswamy N., Tiriveedhi V., Sarma N.J., et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol 2013, 74:1478-1485.
31. Sigdel T.K., Sarwal M.M. Moving beyond HLA: a review of nHLA antibodies in organ transplantation. Hum Immunol 2013, 74:1486-1490.
32. Alheim M., AlMahri A., Nilsson J., et al. The outcome of the endothelial precursor cell crossmatch test in lymphocyte crossmatch positive and negative patients evaluated for living donor kidney transplantation. Hum Immunol 2013, 74:1437-1444.
33. Dragun D., Catar R., Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant 2013, 18:430-435.
34. Billing H., Rieger S., Susal C., et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transplant Int 2012, 25:1165-1173.